Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sonia Quintas

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Medicina Clinica|April 20, 2024
[Migraine treatment consensus document of the Spanish Society of Neurology (SEN), Spanish Society of Family and Community Medicine (SEMFYC), Society of Primary Care Medicine (SEMERGEN) and Spanish Association of Migraine and Headache (AEMICE) on migraine treatment]Robert Belvís, Pablo Irimia, Nuria González, et al.
European Journal of Neurology|June 21, 2022
Machine-learning-based approach for predicting response to anti-calcitonin gene-related peptide (CGRP) receptor or ligand antibody treatment in patients with migraine: A multicenter Spanish studyAlicia Gonzalez-Martinez, Josué Pagán, Ancor Sanz-García, et al.
Pain Medicine (Malden, Mass.)|October 17, 2023
Effectiveness, tolerability, and response predictors of preventive anti-CGRP mAbs for migraine in patients over 65 years old: a multicenter real-world case-control studyAlicia Gonzalez-Martinez, Ancor Sanz-García, David García-Azorín, et al.
European Journal of Neurology|February 7, 2024
Evaluation of the concomitant use of prophylactic treatments in patients with migraine under anti-calcitonin gene-related peptide therapies: The PREVENAC studyAna Beatriz Gago-Veiga, Noelia Lopez-Alcaide, Sonia Quintas, et al.
The Journal of Headache and Pain|June 2, 2023
Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patientsAlbert Muñoz-Vendrell, Sergio Campoy, Edoardo Caronna, et al.
European Journal of Neurology|January 25, 2024
RE-START: Exploring the effectiveness of anti-calcitonin gene-related peptide resumption after discontinuation in migraineCelia Romero Del Rincón, Alicia Gonzalez-Martinez, Sonia Quintas, et al.
Neurology|August 12, 2021
Frequency and Characterization of Movement Disorders in Anti-IgLON5 DiseaseCarles Gaig, Yaroslau Compta, Anna Heidbreder, et al.
Neurology|January 28, 2026
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA CohortEdoardo Caronna, Rut Mas-de-Les-Valls, Gabriella Egeo, et al.
Cephalalgia : an International Journal of Headache|June 19, 2026
Is achieving higher standards in real-world migraine care feasible with anti-CGRP monoclonal antibodies preventive therapies?: Insights from the EUREkA cohortEdoardo Caronna, Rut Mas-de-Les-Valls, Gabriella Egeo, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Medicina Clinica|April 20, 2024
[Migraine treatment consensus document of the Spanish Society of Neurology (SEN), Spanish Society of Family and Community Medicine (SEMFYC), Society of Primary Care Medicine (SEMERGEN) and Spanish Association of Migraine and Headache (AEMICE) on migraine treatment]Robert Belvís, Pablo Irimia, Nuria González, et al.
European Journal of Neurology|June 21, 2022
Machine-learning-based approach for predicting response to anti-calcitonin gene-related peptide (CGRP) receptor or ligand antibody treatment in patients with migraine: A multicenter Spanish studyAlicia Gonzalez-Martinez, Josué Pagán, Ancor Sanz-García, et al.
Pain Medicine (Malden, Mass.)|October 17, 2023
Effectiveness, tolerability, and response predictors of preventive anti-CGRP mAbs for migraine in patients over 65 years old: a multicenter real-world case-control studyAlicia Gonzalez-Martinez, Ancor Sanz-García, David García-Azorín, et al.
European Journal of Neurology|February 7, 2024
Evaluation of the concomitant use of prophylactic treatments in patients with migraine under anti-calcitonin gene-related peptide therapies: The PREVENAC studyAna Beatriz Gago-Veiga, Noelia Lopez-Alcaide, Sonia Quintas, et al.
The Journal of Headache and Pain|June 2, 2023
Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patientsAlbert Muñoz-Vendrell, Sergio Campoy, Edoardo Caronna, et al.
European Journal of Neurology|January 25, 2024
RE-START: Exploring the effectiveness of anti-calcitonin gene-related peptide resumption after discontinuation in migraineCelia Romero Del Rincón, Alicia Gonzalez-Martinez, Sonia Quintas, et al.
Neurology|August 12, 2021
Frequency and Characterization of Movement Disorders in Anti-IgLON5 DiseaseCarles Gaig, Yaroslau Compta, Anna Heidbreder, et al.
Neurology|January 28, 2026
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA CohortEdoardo Caronna, Rut Mas-de-Les-Valls, Gabriella Egeo, et al.
Cephalalgia : an International Journal of Headache|June 19, 2026
Is achieving higher standards in real-world migraine care feasible with anti-CGRP monoclonal antibodies preventive therapies?: Insights from the EUREkA cohortEdoardo Caronna, Rut Mas-de-Les-Valls, Gabriella Egeo, et al.
Pageof 4